Comments on ICER’s 2020 Value Assessment Framework
The conclusions from ICER’s cost-effectiveness evaluations can impact patients’ access to needed treatments. It is imperative, consequently, that ICER’s value assessment framework properly incorporates all potential benefits that a treatment can offer patients, including those benefits that are difficult to quantify or are unquantifiable. Read the Comments
Comments on Draft Scoping Document for Type 2 Diabetes Therapies
As an oral formulation, semaglutide creates convenience benefits for patients that could save time and increase their overall productivity. Specifically, oral semaglutide provides a less complex mode of administration, one that may work better for patients who dislike injections or for whom the cadence of a daily medication is more natural and simpler to maintain than the […]
Comments on Draft Scoping Document for Rheumatoid Arthritis Therapies
The value created by treatment success, in terms of patient outcomes, health care savings, reduced costs on caregivers, and the increased productivity of patients living with RA, all deserve consideration in the analysis. Read the Comments
A Study of the Qualitative Impact of Non-Medical Switching
The story has become a familiar one. A patient with a chronic condition works with his or her doctor to find the right treatment. The condition is stabilized, manageable.
Comments on Draft Evidence Report for Severe Asthma Therapies
Mitigating the high cost of severe asthma requires, in part, access to the appropriate medications. Those include the five monoclonal antibodies indicated for the treatment of patients with moderate to severe asthma that were reviewed in this draft evidence report. These medicines are clinically effective, as the report notes. Specifically, the report cites that the […]
Can ICER Put a Price on Asthma Control?
The Institute for Clinical and Economic Review says new medicine for uncontrolled asthma isn’t worth its cost. But its analysis omits key details. View the Graphic. View Social Graphics.
Comments on Draft Scoping Document for Severe Asthma Therapies
As noted in ICER’s scoping document, uncontrolled asthma is a substantial problem that, according to the Centers for Disease Control and Prevention, afflicts 38.4 percent of children with asthma and 50 percent of adults with asthma. It is not clear from the scoping document, however, that ICER will adequately incorporate into its analysis several key issues associated with uncontrolled asthma.
How Physicians View the 340B Drug Pricing Program
The 340B Drug Pricing Program was designed to encourage health care facilities to provide care for uninsured or underinsured patients. The program works by providing facilities a significant discount on prescription drugs in exchange for their treatment of indigent patients. But whom does 340B really benefit? Has it fulfilled its original intent? And how do […]
What’s Missing from ICER’s Analysis of Migraine Therapies?
The Institute for Clinical and Economic Review says new CGRP inhibitor treatments for chronic and episodic migraine probably won’t be cost effective. But the analysis omits five important components. View the Graphic
Feedback on CGRP Inhibitors as Preventive Treatments for Patients with Migraine
Migraine is one of the most prevalent neurological disorders worldwide, associated with substantial health, sociological and economic consequences. Yet ICER’s draft evidence report, dated April 11, 2018, inaccurately assesses the benefits that migraine patients can receive from CGRP inhibitors. This inaccuracy arises because: (1) the evidence that is necessary to evaluate the cost-effectiveness of CGRP […]
